PULMONARY HYPERTENSION – TREATMENT OPTIONS
DOI:
https://doi.org/10.47144/phj.v44i1-2.117Keywords:
TREATMENT OPTIONSAbstract
Pulmonary Hypertension refers to abnormal increase in pulmonary pressure (mean PA pressure > 25 mmhg
and > 30 mmhg), it can be caused by or associated with variety of conditions). The treatment of Pulmonary
Hypertension depends upon the underlying factors precipitating or causing the disease process. In recent years
many advanced treatment options has been developed to improve the functional class and even survival of
pulmonary hypertension patients.
Pharmacological therapy comprises of primary and advanced therapy. Primary or standard or supportive
therapy is usually used in all pulmonary hypertension groups for symptomatic relief1. Advanced therapies
focus on preventing the underlying disease progression. Patients refractory to all treatment options may
require heart lung transplant.
In last two decades dramatic improvement in treatment options for pulmonary hypertension has occurred but
still lots of question needed to be answered like which patient population benefits most from which particular
therapy, determining when to initiate treatment and establishing optimal treatment sequence or combination
therapy. Still improved disease awareness in addition to novel treatment options has lead to improve outcome
both in terms of functional class and survival for this previously uniformly fatal disease.
Downloads
Downloads
How to Cite
Issue
Section
License
When an article is accepted for publication in the print format, the author will be required to transfer exclusive copyright to the PHJ and retain the rights to use and share their published article with others. However, re-submission of the full article or any part for publication by a third party would require prior permission of the PHJ.
Online publication will allow the author to retain the copyright and share the article under the agreement described in the licensing rights with creative commons, with appropriate attribution to PHJ. Creative Commons attribution license CC BY 4.0 is applied to articles published in PHJ https://creativecommons.org/licenses/by/4.0/